Based on the limited research available, CBN does not appear to suppress REM sleep the way THC does. In fact, animal studies suggest CBN may actually increase REM sleep, making it an unusual cannabinoid in this regard. But the honest answer is that human data on CBN and REM sleep specifically is still thin, and most of what we know comes from rat studies and trials that measured subjective sleep quality rather than sleep stages directly.
What Animal Studies Show About CBN and REM
The most direct evidence comes from a 2024 study published in Neuropsychopharmacology that tracked sleep architecture in rats after CBN administration. The researchers found that CBN increased both non-rapid eye movement (NREM) and REM sleep while decreasing overall wakefulness. Total sleep time went up across both sleep stages, though there was some evidence of initial sleep suppression before the sedative effects kicked in.
This is a notably different pattern from THC, which consistently suppresses REM sleep. In human studies, acute THC administration has been shown to decrease REM sleep percentage by roughly 17.7% while increasing deep sleep. That REM suppression is one reason heavy cannabis users often report vivid, intense dreams when they stop using, a phenomenon called REM rebound. CBN, at least in animal models, doesn’t seem to create this same tradeoff between deeper sleep and lost dream sleep.
How CBN Compares to THC and CBD
Each major cannabinoid interacts with sleep stages differently. THC is the most studied, and its pattern is clear: it pushes you into deeper slow-wave sleep at the expense of REM. For people with nightmares or PTSD, that REM suppression can feel like a benefit. For long-term sleep health, losing REM consistently raises concerns since REM sleep plays a role in memory consolidation, emotional regulation, and cognitive function.
CBD’s effects on REM are less clear. One study found CBD had a positive effect on anxiety-related REM suppression, meaning it helped restore REM sleep that anxiety had disrupted, but it didn’t seem to change NREM sleep. Beyond that, human studies on CBD and sleep architecture are sparse.
CBN sits in a unique position. The rat data showing increases in both NREM and REM suggest it may promote sleep more broadly without selectively cutting into any particular stage. If that pattern holds in humans, it would make CBN fundamentally different from THC as a sleep aid.
What Human Trials Have Measured So Far
Here’s the catch: human trials on CBN have mostly measured how people feel about their sleep, not what their brain waves are doing. A double-blind, placebo-controlled study of 293 participants tested 20 mg of CBN nightly and found it significantly reduced the number of nighttime awakenings and overall sleep disturbance compared to placebo. It did not, however, change how long it took people to fall asleep or how much time they spent awake after initially falling asleep. Importantly, it also didn’t cause daytime fatigue, which suggests it isn’t sedating people into a groggy, low-quality sleep.
That same study tested whether adding CBD to CBN improved outcomes. It didn’t. The combination offered no additional benefit over CBN alone for any sleep measure, which challenges the popular “entourage effect” idea that cannabinoids always work better together.
None of these human studies used polysomnography (the gold-standard sleep lab measurement) to track exactly how much time participants spent in each sleep stage. So while people reported fewer awakenings and better overall sleep, we don’t yet have human brain-wave data confirming whether CBN preserved, increased, or had no effect on their REM sleep.
The CUPID Trial: What’s Being Tested
A clinical trial called CUPID is designed to fill some of these gaps. It’s testing two doses of CBN (30 mg and 300 mg) against placebo in people with insomnia disorder, using a crossover design where each participant tries all three conditions separated by two-week washout periods. The 30 mg dose was chosen to match what’s already sold in U.S. consumer products, while the 300 mg dose was based on preclinical research. Results from this trial should provide much more precise data on what CBN does to sleep architecture in humans, including its effects on REM.
Earlier, smaller studies have tested CBN in combination with other cannabinoids. One trial gave 20 adults with insomnia a nightly liquid containing 20 mg THC, 2 mg CBN, and 1 mg CBD for two weeks. Another open-label study used capsules with 10 mg THC and 5 mg CBN for three weeks. Both reported improved sleep, but the combination formulas make it impossible to isolate what CBN itself was doing, especially at such low doses alongside THC.
REM Rebound Risk When Stopping
One practical concern for anyone using a cannabinoid sleep aid is what happens when you stop. A systematic review in Sleep Medicine Reviews found that withdrawing from active cannabis use was consistently associated with sleep disturbances: shorter total sleep time, longer time to fall asleep, and REM rebound. REM rebound means your brain compensates for suppressed REM by flooding you with extra dream sleep, often producing vivid or disturbing dreams that fragment your night.
This rebound effect is well-documented with THC because THC actively suppresses REM during use. Whether CBN carries the same risk is unknown. If the animal data translates to humans and CBN genuinely doesn’t suppress REM, there may be less rebound to worry about. But no study has specifically tracked what happens to sleep after people stop taking CBN, so this remains speculative.
What This Means in Practice
If you’re considering CBN specifically because you want a sleep aid that won’t cut into your REM sleep, the early signals are cautiously encouraging. Animal research shows CBN increasing REM rather than suppressing it, which is the opposite of what THC does. Human trials confirm that CBN at 20 mg can reduce nighttime awakenings without causing next-day grogginess. But the critical piece of evidence, human sleep-stage data from polysomnography, hasn’t been published yet.
Most CBN products on the market contain between 5 and 30 mg per serving, which falls within the range being studied. The CUPID trial’s inclusion of a 300 mg arm will help clarify whether higher doses behave differently or produce diminishing returns. Until those results arrive, the most accurate summary is that CBN likely does not suppress REM sleep the way THC does, and may even support it, but “likely” is doing real work in that sentence.